Mintz advised global investment firm Sixth Street in connection with its $500 million strategic financing facility with Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing.

The facility includes $100 million funded at close, with up to $300 million available upon achievement of specified clinical, regulatory, and commercial milestones, and an additional $100 million available at Beam’s option during the seven-year term of the agreement.

The long-term, non-dilutive financing is designed to support Beam’s anticipated commercial launch of ristoglogene autogetemcel (ristocel) for sickle cell disease and strengthen the company’s financial position as it advances key programs across its genetic medicine pipeline. The facility matures in early 2033 and provides Beam with significant capital flexibility without scheduled amortization payments.

Mintz served as co-counsel to Sixth Street with Proskauer Rose. The Mintz team was led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, with support from Eric Blythe (Bankruptcy & Restructuring), Joanne Hawana (Regulatory), Tali Tuchin (Licensing), Special Counsel Nick Perricone (Corporate), and Associates Peter Hecker (Intellectual Property) and Joshua Li (Intellectual Property).

Read Sixth Street’s press release here.

About Sixth Street

Sixth Street is a global investment firm with over $75 billion in assets under management and committed capital. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street Healthcare and Life Sciences finances the development and commercialization of innovative therapeutics and invests in healthcare technology companies across all stages of growth. Investments in the sector include Arsenal Biosciences, Biohaven, Blueprint Medicines, Caris Life Sciences, Chroma Medicine, ConcertAI, Datavant, Immunogen, Ironwood, and Mammoth Biosciences, among many others. Founded in 2009, Sixth Street has more than 600 team members including over 250 investment professionals operating around the world. For more information, visit www.sixthstreet.com.

About Mintz

Mintz is a leading 600+ attorney law firm with deep experience in the life sciences industry. We work with leading industry investors and underwriters in innovative financings and offerings, help entrepreneurs launch and protect great ideas, facilitate funding opportunities, and counsel emerging as well as established and public companies in all aspects of their businesses, including regulatory approvals and compliance. To learn more about our team, please visit www.mintz.com.